Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Puma Biotechnology Presented Findings From A Phase I/II Study Of Alisertib And Pembrolizumab For Rb-Deficient Head And Neck Squamous Cell Carcinomas At The 2023 AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Meeting

Author: Benzinga Newsdesk | October 16, 2023 02:25am

Posted In: PBYI